A controlled release system for quercetin from biodegradable poly(lactide-co-glycolide)–polycaprolactone nanofibers and its in vitro antitumor activity. (May 2016)

• Record Type: Journal Article
• Authors: Vashisth, Priya; Singh, Rajesh P; Pruthi, Vikas
• Is Part Of: Journal of bioactive and compatible polymers. Volume 31:Number 3(2016:May)
• Page Start: 260
• Page End: 272
• Publication Date: 2016-05
• Subjects: Quercetin -- nanofibers -- electrospinning -- poly(lactide-co-glycolide) -- polycaprolactone -- antitumor activity; Biomedical materials -- Periodicals; Polymers in medicine -- Periodicals; Polymers -- Periodicals; 547.7
• DOI: 10.1177/0883911515613098
• Languages: English
• ISSNs: 0883-9115

Abstract

Quercetin is a potent natural antioxidant but has limited therapeutic applications due to its short half-life in body fluids. In order to improve the efficacy of quercetin and overcome its shortcomings, quercetin-encapsulated electrospun poly(lactic-co-glycolic acid)–poly(ε-caprolactone) nanofibrous controlled release system was developed using electrospinning technique. Fourier transform infrared spectroscopy, thermogravimetric, and X-ray diffraction analysis suggested the incorporation, thermal stability, and existence of encapsulated quercetin in semicrystalline state in the nanofibers. The release profiles of quercetin from the poly(lactide-co-glycolide)–polycaprolactone nanofibers in phosphate-buffered saline showed controlled release of quercetin up to 120 h. 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay showed an evident inhibition effect of quercetin-encapsulated nanofibers against human hepatocellular carcinoma (HepG2), and the inhibition rate of 29%, 72%, and 80.1% were recorded for 1%, 2%, and 4% quercetin-encapsulated nanofibers, respectively. The formulated drug delivery system could be potentially used as an implantable anticancer drug in clinical applications in the future.